Evercore ISI lowered shares of Augmedix (NASDAQ:AUGX – Free Report) from an outperform rating to an inline rating in a report issued on Tuesday, MarketBeat reports. They currently have $1.50 price objective on the stock, down from their prior price objective of $5.00. Other research analysts also recently issued reports about the stock. Maxim Group […]

Related Keywords

United States , Mian Shakil , Worth Venture Partners , Sg Americas Securities , Acadian Asset Management , Maxim Group , Augmedix Inc , Nasdaq , Norden Group , Oppenheimer Asset Management Inc , Augmedix Company Profile , Free Report , Stock Down , Get Free Report , Asset Management , Augmedix Live , Augmedix Go Assist , Augmedix Prep , Augmedix Daily ,